Skip to main content
Fig. 3 | Cost Effectiveness and Resource Allocation

Fig. 3

From: Methodology and results of cost-effectiveness of LDL-C lowering with evolocumab in patients with acute myocardial infarction in China

Fig. 3

Monte Carlo simulation scatters plot in probabilistic sensitivity analyses of the PEACE study population. (A and B) are the results from the Chinese healthcare perspective, C and D are the results from the Chinese private payer perspective

The dotted line shows the willingness-to-pay threshold, with a slope of CNY 257094 per quality-adjusted life-year gained. CNY, Chinese yuan; QALY, quality-adjusted life-year; WTP, willingness-to-pay

Back to article page